Novo Holdings, the venture capital arm of Novo Nordisk, plans to increase its dealmaking activity in 2024 following the success of the weight-loss drug Wegovy. The fund manager’s CEO, Kasim Kutay, stated that the company expects to do “a fair amount” more deals and to expand by opening a second office in Asia. Novo Holdings will use the significant dividends from Novo Nordisk to execute its strategy of investing half of its capital into the life sciences sector. The company’s principal investment team, which focuses on buyout activity in the life sciences and healthcare sector, will benefit from the cash flows generated by Wegovy. Additionally, Kutay mentioned that Novo Holdings avoids investing in areas already focused on by Novo Nordisk, such as diabetes and obesity, but has invested venture capital in biotech companies active in those areas. The CEO noted that the past year has seen attractive valuations in the biotech sector, which has led to increased activity in the venture space. Novo Holdings is taking advantage of these opportunities to drive its investment strategy.
Revved up: Novo Holdings amplifies dealmaking with Wegovy windfall+
Latest from Blog
Global Excellence: India’s First Private Equity & Venture Capital Centre
TLDR: Key Points: IIM-B signed an MoU with alumnus Mathew Cyriac to set up India’s first Global Centre of Excellence on Private Equity and Venture Capital. The Centre aims to be a
Revolutionizing Travel Startups with Innovative Funding Solutions
TLDR: The New World of Travel Startup Funding Key Points: Flyr raised nearly $300 million in venture capital, highlighting the demand for tech that modernizes industries with recurring revenue. Investors are more
Wealthy Pennsylvanian’s investment secrets for soccer, cars, tech, and more
TLDR: Susquehanna International Group (SIG) has invested in over 500 emerging companies through its three in-house investment funds. SIG’s private funds, including Susquehanna Growth Equity, SIG China, and Susquehanna Asia Venture Capital,
IIM Bangalore’s New Private Equity & Venture Capital Centre Deal
TLDR: IIM Bangalore is getting a new Centre of Excellence – The Tony James Centre for Private Equity and Venture Capital Mathew Cyriac, an alumnus, is supporting the new PEVC centre as
Top Crypto VC Investments: Story Protocol, Sorella, BSX Exchange
Article Summary TLDR: – Story Protocol raises $80 million in series B funding – Sorella Labs secures $7.5 million for Ethereum blockchain tools Crypto VC Roundup: Story Protocol, Sorella, BSX Exchange The